CIBC restated their outperform rating on shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in a research report sent to investors on Thursday. They currently have a $7.00 price objective on the biotechnology company’s stock, up from their prior price objective of $4.00.

A number of other research firms have also recently commented on CATB. Oppenheimer Holdings, Inc. raised their price target on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an outperform rating in a report on Thursday. Citigroup Inc. set a $3.50 price target on Catabasis Pharmaceuticals and gave the company a hold rating in a report on Thursday. Wedbush reissued an outperform rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Wednesday, June 21st. Finally, HC Wainwright raised their price target on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a buy rating in a report on Monday, August 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $5.42.

Catabasis Pharmaceuticals (CATB) opened at 2.49 on Thursday. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $5.51. The stock’s market capitalization is $55.98 million. The company’s 50-day moving average price is $2.00 and its 200 day moving average price is $2.00.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals will post ($1.39) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Given “Outperform” Rating at CIBC” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/09/catabasis-pharmaceuticals-inc-catb-given-outperform-rating-at-cibc.html.

Hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. bought a new stake in shares of Catabasis Pharmaceuticals in the first quarter worth about $144,000. Renaissance Technologies LLC bought a new stake in shares of Catabasis Pharmaceuticals in the first quarter worth about $106,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Catabasis Pharmaceuticals in the second quarter worth about $271,000. 32.90% of the stock is currently owned by hedge funds and other institutional investors.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Stock Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.